Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

CONCLUSION: These data could impact immune target selection, combination therapeutic strategy selection, and selection of predictive biomarkers for immunotherapy in APC.
FUNDING: We acknowledge funding support from Movember, Prostate Cancer UK, The Prostate Cancer Foundation, SU2C, and Cancer Research UK.
PMID: 30179225 [PubMed - as supplied by publisher]

Source: Clinical Prostate Cancer - September 4, 2018 Category: Cancer & Oncology Authors: Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke Tags: J Clin Invest Source Type: research